PCM
FDMT icon

Polymer Capital Management’s 4D Molecular Therapeutics FDMT Stock Holding History

Polymer Capital Management’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-18,035
Closed -$135K – 894
2025
Q4 		$135K Buy
+18,035
New +$183K 0.01% 717

Other funds holding FDMT

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Polymer Capital Management's FDMT Position: Q1 2026 in Review

Polymer Capital Management sold out of 4D Molecular Therapeutics (FDMT) in Q1 2026, closing a stake of 18,035 shares — an estimated $135K sold.

Polymer Capital Management first reported a position in FDMT in Q4 2025 and held it in 1 quarter. The position peaked at $135K in Q4 2025. 153 funds tracked by Wall St. Rank hold FDMT as of Q1 2026.

  • Polymer Capital Management reported no remaining 4D Molecular Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Polymer Capital Management sold 18,035 4D Molecular Therapeutics shares in Q1 2026, an estimated $135K.
  • Polymer Capital Management first reported a position in 4D Molecular Therapeutics in Q4 2025 and held it in 1 quarter.
  • Polymer Capital Management's 4D Molecular Therapeutics position peaked at $135K in Q4 2025.
  • 153 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2026.

Based on Polymer Capital Management's 13F filing for Q1 2026, filed 14 May 2026.